National health care reform initiatives that increasingly aim at cost containment and value-based care delivery are associated with lower reimbursement rates 1 and are further confounded by rising operating costs in the laboratory. These initiatives underscore the need for standardized testing algorithms and decision support mechanisms to assist physicians and pathologists in test selection in various areas of the clinical laboratory. 2 Standardized testing algorithms would reduce inefficiency and control reported overuse of clinical laboratory testing. [3] [4] [5] [6] In particular, the inefficient or inappropriate use of ancillary testing in the diagnostic workup of bone marrow (BM) specimens has been an area of recent interest. 2, 7 This inefficiency is largely due to the lack of data on optimal workflow processes and standardization between laboratories.
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Questions In daily practice, FC and immunohistochemistry (IHC) or in situ hybridization for immunoglobulin light chains are commonly used to determine clonality. All of these methods can also be used for the quantitation of PCs, but FC has been shown to underestimate PC percentages due to differences in sample quality and cellular processing. 8 In addition, the choice of antibodies in an FC panel to be performed on a BM sample with a suspected PCN may vary between institutions. Certain institutions may perform a more comprehensive panel encompassing many lymphoid and myeloid markers in addition to standard PC markers, while others may run a more limited panel targeting only the PC component. Thus, in concert with FC, IHC for CD138 is often performed to more accurately quantify PCs in a BM biopsy specimen. [9] [10] [11] All of these tests vary in cost and turnaround times (TATs), and an optimal combination of testing modalities has not been determined to facilitate the most accurate and cost-effective method for determining PC clonality and quantity. In our institution, various combinations of these methods have been performed on PCN cases to accommodate clinical demand and institutional policy, with evidence-based data playing a small role in the selection of these combinations. We retrospectively analyzed a large number of PCNs from our institution to determine which combination of tests performed and workflow resulted in the most effective usage of testing with regard to cost and without negatively affecting accuracy and TAT for the diagnosis and monitoring of PCNs.
Materials and Methods

Case Selection and Design
A retrospective search of the laboratory information system was performed to retrieve all cases of BM specimens obtained at the University of Utah Hospital/Huntsman Cancer Institute between January 2006 and June 2013 and subsequently worked up for a newly suspected or previously diagnosed PCN. The tests performed on each specimen, including IHC and FC (with number of antibody markers used), were noted, along with the technical charges billed for each test. In a given period, a designated combination of FC and IHC was generally performed, and this workflow combination was consistently applied to all specimens within each period. This study was approved by the University of Utah Health Sciences Internal Review Board (No. 00059758).
Definition of Workflow Periods
Five sequential periods throughout the selected time frame with distinct test combinations and workflow processes were identified ❚Table 1❚:
Period 1 The full FC panel consisted of antibodies against CD45, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, CD10, CD19, CD20, CD13, CD34, CD38, γ-δ, and κ/λ (surface and cytoplasmic), while the limited FC panel consisted of antibodies against CD45, CD19, CD20, CD38, CD52 (in periods 4 and 5 only), CD56, CD117 (in periods 4 and 5 only), CD138, and cytoplasmic κ/λ only, with a gating strategy based on side scatter, CD45, and CD38 to assess PCs ❚Table 2❚. Differential expression of markers, including © American Society for Clinical Pathology CD45, CD19, CD56, CD117, and cytoplasmic light chains, were used to distinguish between clonal and nonclonal PC populations. All FC panels were performed at ARUP Laboratories using five-color FC on an FC 500 flow cytometer with analysis performed using CXP software (both from Beckman Coulter, Brea, CA). IHC was performed using CD138 (clone B-A38; AbD Serotec, Raleigh, NC), k (polyclonal; Dako, Carpinteria, CA), and l (polyclonal, Dako) on a Ventana Ultra autostainer (Ventana Medical Systems, Tucson, AZ).
Comparison Parameters
Mean TAT, mean numbers of IHC tests ordered, and total technical charge (TTC) billed for each case (adjusted to 2013 price using US inflation data) were compared between periods. Cases from patients worked up for the first time were also compared with those from established patients, both within and between periods. All dollar amounts were normalized to an index, with the mean of P1 indexed to 100. Other values such as TAT and mean number of IHC tests performed per case were also indexed to allow for relative comparison.
To determine accuracy of the limited FC panel, a search was performed to find all cases that had addendum or amendment reports. Each addendum/amendment was reviewed to determine whether additional tests were performed, for instance, to characterize a neoplastic lymphoid population not detected on a limited FC study, or if there was discordance between tests. Addenda issued for ancillary tests not pertinent to PC characterization (eg, iron stain, reticulin stain, Congo red stain, or special stains for microorganisms) were excluded. All addenda/amendments were reviewed in conjunction with the case and classified into the following types:
Type I-The add-on markers detected a second process not detected on the limited FC panel.
Type II-The add-on marker did not detect additional abnormalities.
The number of addenda/amendments in each period was used as an indicator of the accuracy of each workflow combination.
Statistical Analysis
The mean TAT, percentage of cases requiring IHC, mean IHC tests per case, and TTC were compared between periods using the Student t test with SAS version 9.3 software (SAS Institute, Cary, NC).
Results
A total of 4,031 BM specimens from 918 patients at the University of Utah Hospital/Huntsman Cancer Institute underwent hematopathology laboratory analysis at ARUP Laboratories for a suspected/previously diagnosed PCN. Of these, 617 (15%) specimens were BM samples from patients worked up for the first time in our institution. The remaining 3,414 (85%) specimens were for follow-up monitoring of patients with a PCN previously diagnosed in our institution. The distribution of these cases among the five workflow periods is shown in ❚Table 3❚. A summary of findings of the comparison parameters for each period is illustrated in Table  3 and ❚Table 4❚.
Impact of Eliminating the FC Panel on TAT, TTC, and IHC Use
Compared with full FC in P1, elimination of FC in P2 resulted in a significant decrease in overall case sign-out TAT from 2.7 to 1.6 days (P < .001, t test) and in TTC from 100 to 73.6 (P < .03, t test) but was associated with a significant increase in the percentage of cases requiring IHC (from 71.7% to 97.4%; P < .001, t test) and the mean number of IHC tests per case (from 2.3 to 3.35 tests; P < .001, t test) ❚Figure 1❚.
Impact of Limited FC Panel on TAT, TTC, and IHC Use
Introduction of a limited FC panel in P3 resulted in a significant reduction in the number of IHC stain orders per case, from 3.35 in P2 to 1.2 in P3 (P < .001, t test) and a slight increase in TTC from 73.6 to 77. 4 (CD52 and CD117) in the limited FC panel in P4 did not result in significant changes in any parameter compared with P3. There were likewise statistically significant (P < .0001, t test) decreases in all of these parameters when P3 and P4 were compared with P1 (Tables 3 and 4) . Although nominally the TTC in P5 showed a significant decrease compared with P4, this was due to a reduction in the reimbursement for FC charges rather than to any particular change in method. When the FC charge per case in P4 was used to calculate the TTC in P5, there was no significant difference (75.6 in P4 to 74.7 in P5). Moreover, the addition of CD52 and CD117 to the limited FC panel in periods 4 and 5 did not result in increased charges to the patient.
Elimination of IHC in Cases With Polyclonal PCs
The elimination of IHC from all cases that were polyclonal by FC in P5 resulted in a marked decrease in the percentage of cases requiring IHC from 98.9% in P4 to 48.3% in P5 (P < .001, t test), with no significant changes in other parameters compared with P4. Likewise, comparing P5 with P1 also showed statistically significant reductions (P < .0001, t test) in TAT, percentage of cases requiring IHC, mean IHC tests per case, and TTC (Tables 3 and 4 ). The savings in IHC technical charges in P5 for the percentage of cases (n = 758) that would have otherwise required IHC is calculated at $193,290 compared with performing CD138/κ/λ IHC and $64,430 compared with performing CD138 IHC only.
Comparison Between New and Established Patients
There was a significantly longer TAT for cases from first-time patients (range, 1.76-3.13 days) compared with those from established patients (range, 1.45-2.25 days) (P < .01 within every period, t test). In P5, 70.3% of first-time cases required IHC compared with only 44.9% of established cases (P < .0001, Pearson c 2 test). This difference was not observed in any other periods in which IHC was performed on all cases. No significant trends were seen in TTC or mean number of IHC tests ordered per case when comparing new and established patients within each period or across different periods for the entire cohort.
Add-On Rate With Limited FC Panel
No addenda/amendments related to FC were identified in P1 and P2 ❚Table 5❚. All identified addenda/amendments occurred in cases that initially had limited FC panels (P3-P5) and required additional markers to be added on or conversion to a full FC panel for various reasons, such as additional abnormalities seen on morphologic review of an entire case or further workup prompted by clinical history.
In P3, two type I cases consisted of a B-cell lymphoproliferative disorder (B-LPD) that was detected on an added-on full FC panel. Two type II cases showed no further findings on add-on full FC. In P4, four type I cases consisted of a B-LPD that was detected on an added-on full FC panel. Four type II cases showed no further findings on add-on full FC, and one type II case showed no further © American Society for Clinical Pathology findings on additional B-cell markers added to the limited FC run. In P5, one type I case showed findings suspicious for a myeloid neoplasm on an added-on full FC panel, another type I case showed increased blasts on additional myeloid markers added to the limited FC run, and four type I cases showed a B-LPD that was detected on an added-on full FC panel. The remaining single type I case in P5 was initially erroneously interpreted as polyclonal PCs on the limited FC panel, but a full FC panel performed to assess for other lesions showed a monoclonal PC population. Eight type II cases showed no further findings on add-on full FC. There were no significant differences in addendum/ amendment rates between new and established patients.
Discrepancy Between FC and IHC in P1 and P3
In P1, only a single case (0.8% of P1 cases) had a hemodilute, suboptimal aspirate that showed no evidence of a PCN by FC but contained 5% monoclonal PCs by IHC on the core biopsy specimen. In P3, only two discrepant cases were found (0.4% of P3 cases). Both of these cases again had hemodilute and hypocellular aspirates that were negative for a PCN by FC, but one contained 90% clonal PCs and the other 25% clonal PCs by IHC on the core biopsy specimen. Furthermore, P3 contained six (1.3%) cases with suboptimal FC samples that demonstrated an absence of PCs, but IHC on the core biopsy specimen showed polyclonal PCs.
Limited FC Panel Along With Reflex Limited IHC Is an Optimal Workflow Process
The P5 workflow pattern with a combination of a limited FC panel accompanied by reflex CD138 IHC only on cases with monoclonal PCs for quantification showed the lowest TTC (64.3) with a comparable low TAT, as well as marked reduction of IHC resource usage. The proposed model showed a minimal impact on accuracy.
Discussion
Our results indicate that introduction of a limited FC panel for PCNs workup results in a significant reduction in TAT, TTC, and number of IHC stains ordered per case compared with using the full FC panel.
Although CD138 IHC performed on BM core or clot sections is more accurate than flow cytometric enumeration for quantification of PCs, 8 it is our experience 12 and that of others 13 that FC is much more sensitive than IHC for detecting PC clonality in small PC populations and confers greater diagnostic accuracy compared with performing only IHC in these cases. In addition, FC can detect monoclonal PC populations admixed with polyclonal PCs based on atypical expression of CD56, CD117, CD45, or CD38.
Hoffmann and Kim 7 recently evaluated the utility of a limited FC strategy in the workup of BM specimens for various hematologic neoplasms, including PCNs, and reported that the limited FC strategy did not have a negative impact on disease detection and resulted in reduced utilization and cost. In our study, only 31 (1.6%) of 2,664 cases from P3 to P5 required addition of a full FC panel or additional lymphoid/myeloid markers not included in the limited PC flow panel. When the actual impact on result reporting was examined, there were only 13 cases with type I add-ons (0.5%) in which the additional markers/full panel detected an additional abnormality not found on the limited FC panel. Additional FC testing was undertaken secondary to correlation with clinical history or morphologic examination by the pathologist. Thus, not only was the limited FC accurate in more than 99% of cases, but it also resulted in a sharp reduction in TTC for FC of almost 40% relative to that of the full FC panel in P1 (Table 3 and Figure 1 ).
We found very low discrepancy rates (three [0.5%] of 581 cases) for cases that were FC negative but IHC positive for clonal PCs in cases from P1 and P3 in which both FC and IHC were performed for clonality assessment. In one of these discrepant cases, there were sheets of PCs (90% of cellularity) that were clonal by IHC. In the other two cases, PCs were fewer in number (5% and 25% cellularity) on the core biopsy specimen, but the FC reports associated with these cases contained comments indicating the hemodilute nature of the sample or lack of immature precursor cells, which served as clues for sample inadequacy. These findings provide further support to the utility of FC in determining PC clonality and speak to the importance of documenting sample quality in the FC report and interpreting results in the context of morphologic assessment.
The lowest TTC was achieved in P5, in which CD138 IHC was performed only to quantify PCs on cases determined to be monoclonal by FC. In addition to the decrease in the IHC charges in P5 compared with P4, the elimination of a significant number of IHC tests also freed IHC laboratory resources to perform other tests. Thus, P5 demonstrates the most optimal and cost-effective combination of tests, resulting in the ability to detect PC clonality with much greater sensitivity using FC than IHC and in reducing utilization of IHC laboratory resources. This combination also does not sacrifice accuracy, as demonstrated by the lack of significant differences in add-on rates (Table 5) between P3 and P5, as well as no significant increase in add-on rates compared with P1, in which full IHC and FC panels were performed.
The results of our study suggest that employing a standardized testing algorithm containing judicious, targeted use of limited FC and IHC tests results in accurate and cost-effective monitoring of PCNs. These findings are in line with a recent study that shows that using evidence-based standard ordering protocols in an interdisciplinary team approach for cytogenetic and molecular studies applied by pathologists on BM specimens resulted in significant decreases in discordant tests, omitted tests, and costs, with an increase in the fraction of positive tests. 2 Our study takes this approach one step further and demonstrates an example of a specific standardized ordering protocol to optimize PCN diagnosis and monitoring in BM samples.
In conclusion, we propose that a workflow pattern ❚Figure 2❚ composed of a limited FC panel for PC clonality along with CD138 IHC for PC quantitation only on cases that are monoclonal or indeterminate by FC achieves the lowest cost structure, optimal TAT, and very low falsenegative rates for the diagnosis and monitoring of PCNs in BM specimens. Of course, accurate diagnosis of PCNs requires correlation with results of all testing modalities and clinical data and should not be based on FC and IHC alone.
